Cover image of the article: Evaluation of Potential Drug-drug Interactions in Patients with Hematologic Malignancies at a Referral Hematology–oncology Hospital: A Single-center Experience

Image Credit:J Rep Pharm Sci

Evaluation of Potential Drug-drug Interactions in Patients with Hematologic Malignancies at a Referral Hematology–oncology Hospital: A Single-center Experience

Authors

Sara Ataei1, Kaveh Ardalani1, Maryam Mehrpooya1, Mojdeh Mohammadi2,*
1Department of Clinical Pharmacy, School of Pharmacy, Hamedan University of Medical Sciences, Hamedan, Iran
2Department of Clinical Pharmacy and Pharmacology and Toxicology, School of Pharmacy, Hamedan University of Medical Sciences, Hamedan, Iran
*Corresponding Author: Corresponding author: Department of Clinical Pharmacy and Pharmacology and Toxicology, School of Pharmacy, Hamedan University of Medical Sciences, Hamedan, Iran. Email:m.mohammadi@umsha.ac.ir

Journal of Reports in Pharmaceutical Sciences:Vol. 8, issue 2; 284-8
Published online:Dec 31, 2019
Article type:Research Article
How to Cite:Ataei S, Ardalani K, Mehrpooya M, Mohammadi M. Evaluation of Potential Drug-drug Interactions in Patients with Hematologic Malignancies at a Referral Hematology–oncology Hospital: A Single-center Experience. J Rep Pharm Sci. 2019;8(2):e147414. doi: https://doi.org/10.4103/jrptps.JRPTPS_67_18

Abstract

Background: Drug-drug interaction (DDI) is a complication that results from the combined use of two or more drugs. DDIs can create problems and increase drug toxicity. In some DDIs, a drug can reduce the effectiveness of other drugs. The treatment regimen of hematologic malignancies includes various medicines. Patients may have another disease and receive other medicines in their treatment regimen, resulting in an elevation of DDI rate. This study was aimed to study the rate, pattern, and probable risk factors for moderate and major interactions. 
Subjects and Methods: In this cross-sectional study, data including type of administrated drugs, type of malignancies, and patients’ demographic data were obtained from medical records of patients referred to Tohid Hospital, Sanandaj, Iran, between 2011 and 2015. Major or moderate interactions were considered eligible for further analysis and minor interactions were excluded. DDIs were identified by Lexicomp software and Drug Interaction Facts book. Data analysis was carried out by descriptive statistics. 
Results: A total of 441 DDIs (moderate to major) were identified in 76 patients. DDIs in men were higher compared to women. In addition, most of the interactions in terms of intensity were moderate (62% of total interactions) and in terms of mechanism were pharmacodynamic (60% of total interactions). Interaction between acetaminophen and granisetron had the highest frequency. Among cancer drugs, cyclophosphamide (7% of total interactions) and among non-cancer drugs, granisetron (10% of total interactions) had the highest frequencies. 
Conclusion: Moderate or major DDIs occurred frequently in patients with blood cancer or related diseases. Most of the found DDIs were categorized as moderate with regard to severity. DDIs identification by the treatment team and replacement of treatment regimen will impose fewer complications on patients and increase patients’ survival. 
 

Highlights

Copyright

© 2019, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

31
Mar
2013
Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country

Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country

Maria Tavakoli-Ardakani,
Kaveh Kazemian,
Jamshid Salamzadeh,
Mahshid Mehdizadeh

Tavakoli-Ardakani M, Kazemian K, Salamzadeh J, Mehdizadeh M. Potential of Drug Interactions among Hospitalized Cancer Patients in a Developing Country. Iran J Pharm Res. 2013;12(Suppl):e125634. doi: https://doi.org/10.22037/ijpr.2013.1284

31
Jan
2013
Potential Drug-drug Interactions in Post-CCU of a Teaching Hospital

Potential Drug-drug Interactions in Post-CCU of a Teaching Hospital

Mohammad Haji Aghajani,
Mohammad Sistanizad,
Mohammad Abbasinazari,
Mahdieh Abiar Ghamsari,
Ladan Ayazkhoo,
Olia Safi
,et al.

Haji Aghajani M, Sistanizad M, Abbasinazari M, Abiar Ghamsari M, Ayazkhoo L, et al. Potential Drug-drug Interactions in Post-CCU of a Teaching Hospital. Iran J Pharm Res. 2013;12(1):e125644. doi: https://doi.org/10.22037/ijpr.2012.1221

26
Aug
2024
A Cross-Sectional Investigation on Drug-Drug Interactions in Prescriptions of Pediatric Outpatient Clinics at a Referral Center in Southern Iran

A Cross-Sectional Investigation on Drug-Drug Interactions in Prescriptions of Pediatric Outpatient Clinics at a Referral Center in Southern Iran

Sara Asadi,
Omid Moradi,
Hossein Amini,
MReza Goodarzian,
Maryam Babaei,
Maral Goodarzian

Asadi S, Moradi O, Amini H, Goodarzian M, Babaei M, et al. A Cross-Sectional Investigation on Drug-Drug Interactions in Prescriptions of Pediatric Outpatient Clinics at a Referral Center in Southern Iran. J Compr Ped. 2024;15(4):e144355. doi: https://doi.org/10.5812/jcp-144355

20
Nov
2010
Evaluation of Pharmacokinetic Drug Interactions in Prescriptions of Intensive Care Unit (ICU) in a Teaching Hospital

Evaluation of Pharmacokinetic Drug Interactions in Prescriptions of Intensive Care Unit (ICU) in a Teaching Hospital

Mohammad Abbasi Nazari,
Neda Khanzadeh Moqhadam

Abbasi Nazari M, Khanzadeh Moqhadam N. Evaluation of Pharmacokinetic Drug Interactions in Prescriptions of Intensive Care Unit (ICU) in a Teaching Hospital. Iran J Pharm Res. 2022;5(3):e128288. doi: https://doi.org/10.22037/ijpr.2010.678

20
Nov
2010
An Investigation of Drug Interactions in Hospital Pharmacy Prescriptions

An Investigation of Drug Interactions in Hospital Pharmacy Prescriptions

Giti Hajebi,
Seyed Alireza Mortazavi

Hajebi G, Mortazavi SA. An Investigation of Drug Interactions in Hospital Pharmacy Prescriptions. Iran J Pharm Res. 2002;1(1):e127579. doi: https://doi.org/10.22037/ijpr.2010.3

More by these authors

Sara AtaeiPubMedScholar
Kaveh ArdalaniPubMedScholar
Maryam MehrpooyaPubMedScholar
Mojdeh MohammadiPubMedScholar
Share
Cited by
Metrics